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Background: The extent to which changes in gene expression can influence cardiovascular disease risk across
different tissue types has not yet been systematically explored. We have developed an analysis pipeline that
integrates tissue-specific gene expression, Mendelian randomization and multiple-trait colocalization to develop
functional mechanistic insight into the causal pathway from a genetic variant to a complex trait.
Methods: We undertook an expression quantitative trait loci-wide association study to uncover genetic variants
associated with both nearby gene expression and cardiovascular traits. Fine-mapping was performed to prioritize
possible causal variants for detected associations. Two-sample Mendelian randomization (MR) was then applied
using findings from genome-wide association studies (GWAS) to investigate whether changes in gene expression
within certain tissue types may influence cardiovascular trait variation. We subsequently used Bayesian multiple-trait
colocalization to further interrogate the findings and also gain insight into whether DNA methylation, as well as
gene expression, may play a role in disease susceptibility. Finally, we applied our analysis pipeline genome-wide
using summary statistics from large-scale GWAS.
Results: Eight genetic loci were associated with changes in gene expression and measures of cardiovascular
function. Our MR analysis provided evidence of tissue-specific effects at multiple loci, of which the effects at the
ADCY3 and FADS1 loci for body mass index and cholesterol, respectively, were particularly insightful. Multiple-trait
colocalization uncovered evidence which suggested that changes in DNA methylation at the promoter region
upstream of FADS1/TMEM258 may also affect cardiovascular trait variation along with gene expression. Furthermore,
colocalization analyses uncovered evidence of tissue specificity between gene expression in liver tissue and
cholesterol levels. Applying our pipeline genome-wide using summary statistics from GWAS uncovered 233
association signals at loci which represent promising candidates for further evaluation.
Conclusions: Disease susceptibility can be influenced by differential changes in tissue-specific gene expression and
DNA methylation. The approach undertaken in our study can be used to elucidate mechanisms in disease, as well
as helping prioritize putative causal genes at associated loci where multiple nearby genes may be co-regulated.
Future studies which continue to uncover quantitative trait loci for molecular traits across various tissue and cell
types will further improve our capability to understand and prevent disease.
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Despite recent efforts in research and development, car-
diovascular disease still poses one of the greatest threats
to public health throughout the world, accounting for
more deaths than any other cause [1]. Since their devel-
opment, genome-wide association studies (GWAS) have
identified thousands of different genetic loci associated
with complex disease traits [2]. An example of their suc-
cessful application within cardiovascular research is the
identification of numerous genetic variants associated
with low-density lipoprotein (LDL) cholesterol levels [3],
which is a causal mediator along the coronary heart dis-
ease progression pathway [4, 5]. However, the functional
and clinical relevance for the vast majority of GWAS re-
sults are still unknown, emphasizing the importance of
developing our understanding of the causal pathway
from single nucleotide polymorphism (SNP) to disease.
A large proportion of associations detected by GWAS
are located in non-coding regions of the genome [6], sug-
gesting that the underlying SNPs influence complex traits
via changes in gene regulation [7]. Recent efforts have in-
corporated messenger ribonucleic acid (mRNA) expres-
sion data into analyses to determine whether SNPs
identified by GWAS influence levels of gene expression
(i.e. whether they are expression quantitative trait loci
(eQTL)) [8]. Novel methods have integrated eQTL data
with summary association statistics from GWAS [9] to
identify genes whose nearby (cis) regulated expression is
associated with traits of interest (widely defined as variants
within 1 Mb on either side of a gene’s transcription start
site (TSS)) [10]. These are referred to as
transcriptome-wide association studies (TWAS). TWAS
include distinct methods to predict gene expression using
reference panels. In this study, we have performed a simi-
lar analysis, except instead of using predicted gene expres-
sion, we have identified eQTL from a reference
population and evaluated their direct association with
complex traits. Therefore, to differentiate between this ap-
proach and TWAS, we describe the approach as an
eQTL-wide association study (eQTLWAS).
A recent paper has highlighted some limitations that
may be encountered by studies integrating transcriptome
data to infer causality [11], such as intra-tissue variability
and co-regulation amongst proximal genes, making it
challenging to disentangle putative causal genes for asso-
ciation signals. This exemplifies the importance of devel-
oping methods that investigate tissue specificity and
co-regulation of association signals. Therefore, there
needs to be further research into the most appropriate
manner to harness eQTL data (across multiple tissue
and cell types) in order to improve the biological inter-
pretation of GWAS findings.
In this study, we have developed an analysis pipeline
to investigate trait-associated eQTL and postulate fivepotential scenarios that can help explain them (Fig. 1).
Firstly, we identify associations between lead eQTL
based on a reference population (such as the Framing-
ham Heart Study (n = 5257) [8] used in this study) and
complex traits. Regions where associations are detected in
this analysis are fine mapped to prioritize causal variants re-
sponsible for effects. We then investigate the relationship
between gene expression and complex traits at the loci of
interest by applying the principles of Mendelian
randomization (MR), a method which uses genetic variants
associated with an exposure as instrumental variables to
infer causality amongst correlated traits [12, 13]. A recent
development in this paradigm is two-sample MR, by which
effect estimates on exposures and outcomes are derived
from two independent datasets, allowing researchers to ex-
ploit findings from large GWAS consortia [14]. Applying
this approach can therefore be used to help infer whether
changes in gene expression (our exposure) may influence a
complex trait identified by GWAS (our outcome) (Add-
itional file 1). Furthermore, as tissue specificity is funda-
mental to understanding causal mechanisms involving gene
expression, we have used data from the Genotype Tissue
Expression Project (GTEx) [15] in a number of tissues that
could be important in cardiovascular disease susceptibility
(Additional file 2: Table S1) to try and disentangle
co-regulation amongst proximal genes (i.e. differentiating
between scenarios 1, 2 and 3 (Fig. 1a)). We refer to this ap-
proach as tissue-specific MR, which should prove increas-
ingly valuable in investigating both the determinants and
consequences of changes in tissue-specific gene expression
as sample sizes increase [12].
We subsequently apply colocalization analyses [16] at
each locus of interest to evaluate whether gene expres-
sion and complex trait share the same causal variant.
This is opposed to the alternative explanation, which is
that association signals may be a product of linkage dis-
equilibrium (LD) between two separate causal variants
(Fig. 1a: scenario 4). This analysis can also complement
the findings from the MR analysis, particularly given that
the majority of genes can only be instrumented with a
single eQTL using GTEx data. In addition, there has
been a recent interest in the impact that DNA methyla-
tion may have on cardiovascular disease risk via modifi-
cations in gene expression [17]. Therefore, we apply
multiple-trait colocalization (moloc) [16] at each locus
to simultaneously investigate whether the same under-
lying genetic variant is driving the observed effect on all
three traits of interest (i.e. the cardiovascular trait, gene
expression and DNA methylation).
Uncovering evidence suggesting that DNA methylation
and gene expression may be working in harmony to in-
fluence complex traits can improve the reliability of
causal inference in this field, as it suggests there may be
underlying mechanisms which are consistent with
Fig. 1 Analysis pipeline and explanations for observed associations between single nucleotide polymorphisms (SNPs) and traits. a Five potential
scenarios that could explain findings from the expression quantitative trait loci-wide association study (eQTLWAS): 1) The genetic variant
influences the trait, mediated by the expression of a single gene at a locus. 2) The genetic variant influences the trait via multiple genes which
are co-regulated with one another. 3) The genetic variant influences the trait via a single gene which is co-regulated with other non-causal
genes. 4) The genetic variant that influences the trait is in linkage disequilibrium with another variant which is responsible for the changes in
gene expression levels. 5) The genetic variant influences both gene expression and the trait outcome by two independent biological pathways
(horizontal pleiotropy). b Flow diagram illustrating the analysis pipeline used to interrogate the causal pathway from SNP to trait. eQTLWAS was
performed to uncover genetic variants associated with nearby gene expression and complex trait. Fine-mapping was implemented to identify
potential causal variants. Mendelian randomization (MR) analyses were performed to interrogate scenarios 1, 2 and 3. Multiple-trait colocalization
explored shared causal variants between traits (scenario 4). We were unable to investigate horizontal pleiotropy due to an insufficient number of
instruments (scenario 5)
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tional repressor). However, a major challenge in this
paradigm is the lack of accessible tissue-specific DNA
methylation/methylation QTL (mQTL) data akin to
GTEx for gene expression. Previous studies have investi-
gated the potential mediatory role of DNA methylation
between a genetic variant and gene expression using
eQTL and mQTL data derived from the blood which
may act as a proxy for other tissue types [18–20]. More-
over, other studies have demonstrated a surprisingly high
rate of replication between mQTL derived from the
blood and more relevant tissue types for a complex trait
of interest [21]. We have therefore undertaken moloc
analyses using eQTL derived from both blood and
cardiovascular-specific tissue types. Finally, it is alsoimportant to note that, along with other approaches
which apply causal methods to molecular data, we are
currently unable to robustly differentiate mediation from
horizontal pleiotropy (Fig. 1a: scenario 5) [12, 22]. How-
ever, within this pipeline, we will be able to accommo-
date additional eQTL as instrumental variables derived
from future larger studies in order to address this.
In this study, we demonstrate the value of our pipeline
by undertaking an applied investigation attempting to
link genetic variants to cardiovascular risk factors via
changes in gene regulation. We have used the Avon
Longitudinal Study of Parents and Children (ALSPAC)
as our discovery cohort which has early life measures of
cardiovascular function that were analysed as complex
traits. Associations detected between eQTL and
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tremely valuable for disease prevention and healthcare.
We used ~ 19,000 cis-eQTLs observed in adults at risk
of cardiac events from the Framingham Heart Study [8]
for our eQTLWAS to ascertain whether they influence
these cardiovascular traits in young individuals (age ≤ 10
in ALSPAC). We have further evaluated the results using
our analysis pipeline (Fig. 1b) by harnessing summary
statistics from large-scale GWAS to demonstrate the
value of our approach and validate findings in independ-
ent samples. Finally, we apply our pipeline in a
genome-wide manner using the findings from large-scale
GWAS, which may prove useful in prioritizing putative
causal genes for further evaluations by future studies.
Methods
The Avon Longitudinal Study of Parents and Children
Detailed information about the methods and procedures
of ALSPAC is available elsewhere [23–25]. In brief,
ALSPAC is a prospective birth cohort study which was
devised to investigate the environmental and genetic fac-
tors of health and development. In total, 14,541 preg-
nant women with an expected delivery date of April
1991 and December 1992, residing in the former region
of Avon, UK, were eligible to take part. Participants
attended regular clinics where detailed information and
bio-samples were obtained. The study website contains
details of all the data that is available through a fully
searchable data dictionary [26]. All procedures were eth-
ically approved by the ALSPAC Ethics and Law Commit-
tee and the Local Research Ethics Committees. Written
informed consent was obtained from all participants.
Genetic data
All children were genotyped using the Illumina Human-
Hap550 quad genome-wide SNP genotyping platform.
Samples were removed if individuals were related or of
non-European genetic ancestry. Imputation was per-
formed using Impute V2.2.2 against a reference panel
from 1000 Genomes [27] phase 1 version 3 [28]. After
imputation, we filtered out variants and kept those with
an imputation quality score of ≥ 0.8 and minor allele fre-
quency (MAF) > 0.01.
Phenotypes
The methods and procedures to acquire data for the 14
phenotypes analysed in this study are as follows. All
measurements were obtained at the ALSPAC clinic.
Height and weight were measured at age 7 (mean age
7.5, range 7.1–8.8). Height was measured to the nearest
0.1 cm with a Harpenden Stadiometer (Holtain Cross-
well), and weight was measured to the nearest 0.1 kg on
Tanita electronic scales. Body mass index (BMI) was cal-
culated as (weight [kg]/(height [m]2). Non-fasting bloodsamples were taken at age 10 (mean age 9.9, range 8.9–
11.5). The methods on the assays performed on these
samples which included total cholesterol, high-density
lipoprotein cholesterol, LDL cholesterol (calculated
using the Friedewald equation [29]), very low-density
lipoprotein (VLDL) cholesterol, triglycerides, apolipo-
protein A1 (ApoA1), apolipoprotein B (ApoB), fasting
glucose, fasting insulin, adiponectin, leptin, C-reactive
protein (CRP) and interleukin 6 (IL-6) have been de-
scribed previously [30].
The Framingham Heart Study
We identified over 19,000 pruned lead cis-eQTLs from
Joehanes et al. [8] who provide in-depth details of the
Framingham Heart Study and their analysis plan in their
paper. Trans-eQTLs were not considered for our ana-
lysis to reduce the likelihood of horizontal pleiotropy in-
fluencing our findings and also to reduce the burden of
multiple testing [31]. This eQTL data was chosen for the
initial analysis in ALSPAC due to the larger sample size
of transcriptome data from the Framingham Heart Study
(n = 5257) using whole blood in comparison to GTEx
sample sizes for other tissue types. This allowed us to
maximize statistical power to detect association signals
which we were then subsequently able to evaluate in de-
tail using data from other tissue types.
The Genotype Tissue Expression Project
GTEx is a unique open-access online resource with gene
expression data for 449 human donors (83.7% European
American and 15.1% African American) across 44 tis-
sues. Sample sizes vary between tissues, thus affecting
statistical power to identify eQTL. In-depth information
on the materials and methods for GTEx is available in
the latest publication [15]. In short, RNA sequencing
samples were sequenced to a median depth of 78 million
reads. This is suggested to be a credible depth to quan-
tify accurately genes that may have low expression levels
[32]. DNA was genotyped at 2.2 million sites and im-
puted to 12.5 million sites. We used GTEx eQTL data
(v6p) in the Mendelian randomization and multiple-trait
colocalization analyses (Fig. 1b). The mean donor age
for all tissues included in this analysis resided between
50 and 55 years (range 20–79).
Statistical analysis
Data from ALSPAC were initially cleaned using STATA
[version 15], and outliers defined as ± 4 standard devia-
tions from the mean were removed. We plotted histo-
grams to check the data for normality and where
necessary applied log transformation. Using PLINK [ver-
sion 1.9] [33, 34], we undertook an age- and
sex-adjusted eQTLWAS to evaluate the association be-
tween cis-eQTLs known to influence gene expression
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rection to account for multiple testing which equated
to 0.05/the total number of tests undertaken. Using a
script derived from the qqman R package [35], the re-
sults were plotted using a Manhattan plot. We under-
took fine-mapping across the region 1Mb either side
of each lead SNP identified from our eQTLWAS
using FINEMAP software [36]. As FINEMAP requires
LD statistics between variants in a region, we per-
formed this analysis in the ALSPAC dataset where we
had individual-level data to compute LD. This was
opposed to using the summary-level data from the
large-scale GWAS which requires a reference popula-
tion such as the 1000 Genomes Project as this has
been reported to influence false-positive rates [37]. In
all FINEMAP analyses, we used the default setting
which outputs a maximum of five putative causal
variants.
Tissue-specific Mendelian randomization analysis
To investigate potential causal genes at association sig-
nals detected in our eQTLWAS, we applied the princi-
ples of MR using the Wald ratio method [38]
(Additional file 1: Fig. S1) to assess whether changes in
tissue-specific gene expression (eQTLs as instrumental
variables) may be responsible for effects on associated
traits. Furthermore, it may help discern whether mul-
tiple proximal genes at a region are contributing to trait
variation or whether they are co-regulated with the
causal gene(s), i.e. scenario 3. Firstly, for each lead
eQTL from the eQTLWAS, we used tissue-specific data
from GTEx to discern whether they were cis-eQTL for
genes in tissue types which may play a role in the path-
ology of cardiovascular disease (P < 1 × 10−4). The tissue
types evaluated were as follows: adipose–subcutaneous;
adipose–visceral (omentum); liver, pancreas, artery–
coronary; artery–aorta; heart–atrial appendage; and
heart–left ventricle. In addition to this, we ran an add-
itional analysis for the association with BMI but investi-
gating the effects in the following brain tissues:
pituitary, anterior cingulate cortex (BA24) and frontal
cortex (BA9).
For this analysis, we used data from large-scale
GWAS; a full list of these with details can be found in
Additional file 2: Table S2) [39–41]. These analyses were
undertaken using the MR-Base platform [42]. The only
trait we were unable to assess in this analysis was IL-6,
due to the lack of GWAS summary statistics for this
trait. We applied a multiple testing threshold to the MR
results based on the number of tests undertaken. We
plotted the results from the validation analysis using vol-
cano plots from the ggplot2 package in R [43]. We also
applied the Steiger directionality test [44] to discern
whether our exposure (i.e. gene expression) wasinfluencing our outcome (i.e. our complex trait) as op-
posed to the opposite direction of effect. The null hy-
pothesis for this test is that the r2 for the SNP-exposure
and SNP-outcome effects are the same. The alternative
hypothesis is that they are different more than we would
expect by chance.
We then undertook a validation analysis by repeating
MR analyses using ALSPAC data. As cardiovascular trait
data is therefore obtained at an earlier stage in the life
course compared to the tissue-specific expression data,
any associations detected in the validation analysis sug-
gest genetic liability to cardiovascular risk via changes in
gene expression.
Multiple-trait colocalization
Blood samples were obtained from 1018 ALSPAC
mothers as part of the Accessible Resource for Inte-
grated Epigenomics Studies (ARIES) [45] from the
‘Focus on Mothers 1’ time point (mean age = 47.5).
Epigenome-wide DNA methylation was derived from
these samples using the Illumina HumanMethylation450
(450K) BeadChip array (n = 742 after quality control).
From this data, we obtained effect estimates for all gen-
etic variants within a 1-Mb distance of lead eQTL from
the eQTLWAS and proximal CpG sites (again defined
as < 1Mb). We then used the moloc [16] method to in-
vestigate two questions:
1) Is the same underlying genetic variant influencing
changes in both proximal gene expression and
cardiovascular trait (i.e. investigating scenario 4
(Fig. 1a))?
2) Does the genetic variant responsible for these
changes also appear to influence proximal DNA
methylation levels, suggesting that changes in this
molecular trait may also play a role along the causal
pathway to disease?
As such, at each locus, we applied moloc using genetic
effects on 2 different molecular phenotypes (gene ex-
pression and DNA methylation (referred to as eQTL
and mQTL respectively)) along with the associated car-
diovascular trait from our GWAS summary statistics.
Since we evaluated three traits in this analysis (i.e. gene
expression, DNA methylation and cardiovascular trait),
moloc computed 15 possible configurations of how gen-
etic variation may influence these traits (Additional file 2:
Table S3). Detailed information on how these are calcu-
lated can be found in the original moloc paper [16]. For
each independent trait-associated locus, we extracted ef-
fect estimates for all variants within 1Mb distance of the
lead eQTLWAS hit, for all molecular phenotypes and
relevant cardiovascular GWAS traits. We subsequently
applied moloc in a gene-centric manner, by mapping
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side of our eQTLWAS hit. This approach was applied to
all gene-CpG combinations, within each region of inter-
est. We ran this analysis twice, once using expression
data from whole blood and again using expression data
from a tissue type which was associated with the corre-
sponding trait in the tissue-specific MR analysis (Add-
itional file 2: Table S4).
Only the regions with at least 50 SNPs (MAF ≥ 5%) in
common between all three datasets (i.e. gene expression,
DNA methylation and cardiovascular trait) were assessed
by moloc based on the recommendations by the authors.
We computed summed posterior probability of associa-
tions (PPAs) for all scenarios where GWAS trait and gene
expression colocalized. When summed PPAs were ≥ 0.8,
we reported the findings as evidence that genetic variation
was influencing cardiovascular traits via changes in gene
expression. Furthermore, when summed PPAs relating to
DNA methylation were ≥ 0.8, there was evidence that
DNA methylation may also reside on the causal pathway
to complex trait variation via changes in gene expression.
In all analyses, we used prior probabilities of 1e−04, 1e−06
and 1e−07 as recommended by the developers of moloc
based on their simulations [16].
Applying the analytical pipeline genome-wide using
findings from large-scale consortia
Finally, we demonstrate how our approach can be ap-
plied genome-wide using summary level statistics avail-
able from large-scale GWAS consortia. Lead eQTLs
were identified across nine tissue types from the GTEx
consortium (the eight described above as well as whole
blood), and their association with complex traits was
evaluated using findings from the GWAS described in
Additional file 2: Table S2. When an eQTL could not be
located using these summary statistics, we attempted toTable 1 Results of the expression quantitative trait loci-wide associa
gene expression and cardiovascular traits in ALSPAC
Tag SNP Gene(s) Trait
rs646776 SORT1; CELSR2; PSRC1 Total cholesterol
rs646776 SORT1; CELSR2; PSRC1 LDL cholesterol
rs646776 SORT1; CELSR2; PSRC1 ApoB
rs12129500 IL6R IL-6
rs11693654 ADCY3; NCOA1; CENPO BMI
rs80026582 LPL Triglycerides
rs80026582 LPL VLDL cholesterol
rs600038 ABO IL-6
rs174538 FADS1; FADS2; TMEM258 Total cholesterol
rs2727784 APOA1; TAGLN ApoA1
rs10419998 GATAD2A; MAU2; TM6SF2 ApoB
Abbreviations for the column headings from left to right: single nucleotide polymo
for this effect, observed effect size, standard error of the effect size, P value for thelocate a proxy SNP (i.e. r2 ≥ 0.8) based on a reference
panel of European individuals from the 1000 Genomes
Phase 3 Project [27].
Associations between eQTL and complex traits which
survived multiple testing were analysed using MR. Fur-
thermore, moloc was applied as before using data from
the ARIES project. Fine-mapping was not undertaken in
this analysis as we did not have individual-level data
from these GWAS, and using a reference panel in these
situations has been reported to increase the likelihood of
spurious findings [37].Results
Identifying putative causal genes for measures of
cardiovascular function
We carried out 273,742 tests to evaluate the association
between previously identified cis-eQTLs [8] with 14 car-
diovascular traits in turn within ALSPAC (19,553
cis-eQTLs × 14 traits). After multiple testing corrections,
we identified 11 association signals across 8 unique gen-
etic loci which provided strong evidence of association
(P < 1.8 × 10−7 [Bonferroni-corrected threshold, P < 0.05/
273,742]). These results can be found in Table 1 and are
illustrated in Fig. 2. The region near SORT1 was associ-
ated with total cholesterol, LDL cholesterol and ApoB.
Additionally, the LPL region was associated with both
triglycerides and VLDL cholesterol.
We undertook fine-mapping 1Mb either side of the
lead SNP at each locus identified in our initial analysis
to investigate which SNP(s) may be driving the observed
effects of complex traits. PPAs from FINEMAP [36] sug-
gested that there was most likely only a single variant in-
fluencing trait variation for 7 of the 11 total loci. For the
other 4 loci, FINEMAP suggested there may be multiple
variants influencing traits (Additional file 2: Table S5).tion study (eQTLWAS) between genetic variants influencing
Sample size Beta SE P value
4543 − 0.099 0.016 1.10 × 10−9
4543 − 0.110 0.015 7.74 × 10−14
4546 − 2.695 0.328 2.66 × 10−16
4503 − 0.126 0.018 4.96 × 10−12
6387 0.200 0.036 3.57 × 10−8
4334 − 0.101 0.018 1.49 × 10−8
4334 − 0.100 0.018 1.57 × 10−8
4496 − 0.207 0.021 4.12 × 1022
4539 − 0.080 0.015 5.03 × 10−8
4018 3.047 0.468 8.05 × 10−11
4404 − 2.024 0.376 7.96 × 10−8
rphism, gene or gene cluster associated with SNP, associated trait, sample size
observed effect
Fig. 2 Manhattan plot illustrating observed associations between expression quantitative trait loci (eQTLs) and cardiovascular traits in the ALSPAC
cohort. Analyzed SNPs are plotted on the x-axis ordered by chromosomal position against −log10 P values which are plotted on the y-axis. SNPs
that survived the multiple testing threshold (1.8 × 10−7—represented by the red horizontal line) are coloured according to their associated trait
and annotated with potential causal gene symbols
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Mendelian randomization
We undertook 54 MR analyses across all tissues and
complex traits from large-scale GWAS and identified 34
associations between tissue-specific gene expression and
cardiovascular traits (P < 9.3 × 10−4 (i.e. 0.05/54 tests)
(Additional file 2: Tables S6-S16). In the separate valid-
ation analysis in ALSPAC, we observed consistent direc-
tions of effect for 30 of the associations. The potential
value of this approach in terms of disentangling causal
genes (i.e. scenarios 2 and 3 (Fig. 1a)) was exemplified at
the BMI-associated region on chromosome 2. Of the 3
cis- and potentially causal genes for this signal, only
ADCY3 provided strong evidence of being the putative
causal gene in two types of adipose tissue (adipose sub-
cutaneous (P = 6.8 × 10−40) and adipose visceral (P =
3.1 × 10−48)) (Additional file 1: Fig. S2). This suggests
that changes in ADCY3 expression in adipose tissue
could influence BMI levels. In contrast, there was a lack
of evidence that changes in NCOA1 expression in the
analysed tissue types influence BMI. We were unable to
undertake MR of CENPO expression in this analysis as
were unable to harmonize the effect estimates between
exposure and outcome. As an additional analysis, we re-
peated the MR on BMI using eQTL effect estimates de-
rived from ADCY3 expression in brain tissue (pituitary),
although there was limited evidence of association (beta
(SE), 0.008 (0.006); P, 0.177).
Additional file 1: Fig. S2 also illustrates the results ob-
served at the cholesterol associated region on chromo-
some 11. There was evidence that FADS1 expression was
associated with total cholesterol in three different tissues(adipose subcutaneous (P = 2.2 × 10−40), heart left ventricle
(P = 1.0 × 10−35) and pancreas (P = 2.2 × 10−40)). Interest-
ingly, the strength of evidence was comparable between
subcutaneous adipose and pancreas tissues despite the dif-
ferences in GTEx sample sizes (pancreas 220 and adipose
subcutaneous 385) (Additional file 1: Fig. S3). TMEM258
expression provided strong evidence of association in one
tissue type (adipose subcutaneous (P = 7.2 × 10−34)),
whereas association between FADS2 expression and total
cholesterol was observed in multiple tissue types (adi-
pose—subcutaneous (P = 5.1 × 10−11), adipose—visceral
(P = 4.2 × 10−20), artery—aorta (P = 5.8 × 10−10), heart—
atrial appendage (P = 6.3 × 10−5) and pancreas (P = 6.3 ×
10−5)). The most parsimonious explanation may be that
multiple genes at this locus influence cholesterol levels;
however, further analyses are required to robustly differen-
tiate between scenarios 2 and 3 here (Fig. 1a).
At other loci evaluated (Additional file 1: Figures
S4-S10), LPL showed evidence of association with tri-
glycerides in a single tissue (adipose subcutaneous (P =
9.6 × 10−168)) implying that this effect may be more
tissue-specific compared to those observed at other loci
in this study (Additional file 1: Figs. S9 and S10, Add-
itional file 2: Tables S15 and S16). On chromosome 1,
there was strong evidence that gene expression in the
liver influences total cholesterol (Additional file 1: Fig.
S7) and LDL (Additional file 1: Fig. S8) (P < 3.22 ×
10−120). However, this was observed for all three genes
in the region (SORT1, CELSR2 and PSRC1). In these
analyses alone, we were unable to determine whether a
particular gene is driving this observed effect, with the
other proximal genes being co-regulated, or whether
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nario 2 (Fig. 1a)). However, evidence from the literature
implicates SORT1 as the most likely causal gene for this
association signal [11, 46]. Our MR results from
ALSPAC provided evidence between ABO expression
and IL-6 in four different tissues (Additional file 2: Table
S13). Although, caution is required when interpreting
this signal based on previous evidence across a diverse
range of traits [47]. Finally, to test the direction of effect
at each locus (i.e. are changes in gene expression causing
changes in trait or vice versa), we applied the causal dir-
ection test [44]. In all scenarios, the test provided evi-
dence that gene expression influences traits at these loci
rather than the opposite direction of effect (Add-
itional file 2: Tables S6-S16).
Using multiple-trait colocalization to uncover evidence of
shared causal variants between cardiovascular and
intermediate traits
We identified evidence of colocalization (PPA = ≥ 0.8) for
seven unique genes across five loci across various tissue
types (Additional file 2: Tables S17-S21). Building upon
the results from the tissue-specific MR analysis, we found
strong evidence that ADCY3 is the functional gene for the
BMI-associated signal on chromosome 2 (maximum PPA
of 0.99 between gene expression and BMI [hypothesis 11:
see Additional file 2: Table S3 for explanation]). We iden-
tified evidence of colocalization between BMI and ADCY3
expression in both whole blood and subcutaneous adipose
tissue. There was also evidence that distributions between
DNA methylation at cg04553793 (at the promoter region
of ADCY3) colocalized with BMI and ADCY3 expression
in whole blood (PPA = 0.88 [hypothesis 14]). However, the
lead mQTL for this observed effect (rs13401333) was not
correlated with the lead eQTL and GWAS hit (rs6745073,
r2 = 0.02), which suggests that in-depth analysis with mul-
tiple tissue types is necessary to confirm whether DNA
methylation influences disease susceptibility at this locus.
There was also evidence that changes in DNA methy-
lation at a CpG site in the promoter region for FADS1
(cg19610905) colocalized with total cholesterol variation.
There was evidence of colocalization for all three traits
using gene expression for TMEM258 (PPA = 0.85)
(Fig. 3a), where the lead GWAS variant (rs174568) and
mQTL were in perfect LD (rs1535, r2 2 = 1). This effect
was only observed in whole blood. Evidence of colocali-
zation between all three traits using FADS1 expression
narrowly missed the cut-off (PPA = 0.77). Finally, we
found limited evidence that changes in DNA methyla-
tion at this CpG site colocalized with FADS2 expression,
although as with the previously evaluated locus, this was
not surprising given that cg19610905 is located down-
stream of FADS2. Gene expression of TMEM258 in
whole blood was negatively associated with DNAmethylation at cg19610905. The directionality test sug-
gested that DNA methylation influences TMEM258 ex-
pression at this locus rather than the opposite direction
of effect (P < 1 × 10−16).
We did not identify evidence in the colocalization ana-
lysis suggesting that DNA methylation plays a role in
trait variation at the SORT1 region. However, there was
evidence of tissue specificity in liver tissue which sup-
ports the evidence identified in our MR analysis. The
first plot in Fig. 3b illustrates how the effects on SORT1
gene expression and total cholesterol at this region colo-
calizes in liver tissue. In contrast, the neighbouring plot
depicts the same analysis but in whole blood, whereby
no evidence of colocalization was detected. Furthermore,
we see the same tissue-specific colocalization for the ef-
fect on ApoB in the same region (Additional file 2: Table
S17). The CELSR2 gene showed similar evidence for tis-
sue specificity in the liver, whereas PSRC1 expression
colocalized with GWAS traits in both the whole blood
and liver.
Genome-wide application using findings from large-scale
consortia
Applying our pipeline using publicly available GWAS
findings involved 256,011 tests between eQTL across 9
tissue types and 7 cardiovascular traits. Overall, 233 as-
sociations (across 80 unique genes) survived multiple
testing corrections (P < 1.9 × 10−07 (0.05/256,011)) that
also provided evidence of colocalization (i.e. PPA ≥ 0.8).
This suggests that gene expression and cardiovascular
traits share a causal variant at their loci (Additional file 2:
Table S22). Furthermore, 156 of the 233 associations
which colocalized provided evidence that the underlying
causal variants at their loci may also influence nearby
DNA methylation levels (PPA ≥ 0.8 for scenario GEM).
Figure 4 contains Manhattan plots illustrating the
associations with BMI across 3 different tissue types
(adipose–subcutaneous; adipose–visceral omentum; and
whole blood).
Investigating the findings with BMI suggests that there
are loci which are most likely attributed to scenario 3
over alternative explanations, given that they were the
only genes in their region which provided evidence of
colocalization. An example of this is SLC5A11 which
was associated with BMI using gene expression from six
different tissue types (all PPA > 0.90). There were also ef-
fects which may be attributed to scenario 2 that appear
to be more tissue-specific, such as POMC, where evi-
dence of association was only detected using data de-
rived from pancreatic tissue (PPA = 0.92). Furthermore,
these analyses may help elucidate novel loci in disease
risk, such as the CILP2 gene (PPA = 0.83). The GWAS
SNP at this locus does not meet conventional GWAS
corrections (P = 7.16 × 10−08), although the reduced
Fig. 3 Multiple-trait colocalization analyses between cardiovascular traits and molecular phenotypes. a Evidence of colocalization
between TMEM258 expression and total cholesterol (left) as well as DNA methylation at cg19610905 and total cholesterol (right)
using data derived from whole blood. b Evidence of colocalization between SORT1 expression using data derived from the liver and
total cholesterol (left). However, this evidence diminished when undertaking the same analysis for SORT1 expression data derived
from whole blood (right). Abbreviations: TC, total cholesterol; eQTL, expression quantitative trait loci; mQTL, methylation quantitative
trait loci
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expression data strengthens the evidence that it may in-
fluence disease risk. However, there were also loci where
multiple genes provided evidence of colocalization, such
as TUFM and SULT1A2 located on chromosome 16 (PPA
= 0.93 and 0.99 respectively). Further analyses are there-
fore necessary to help distinguish whether there are mul-
tiple causal genes at these loci (i.e. scenario 2) or whether
a single causal gene is responsible for the association sig-
nal (scenario 3).
Discussion
In this study, we have developed an analysis pipeline to
elucidate transcriptional mechanisms in disease whichcan help explain the functional relevance of GWAS find-
ings. This is achieved by adapting the principles of MR
in evaluating the putative effect of tissue-specific gene
expression on complex traits, which can be complemen-
ted with moloc and harnessing large-scale summary sta-
tistics. We demonstrate the value of this approach by
evaluating 11 signals identified in an eQTLWAS study
undertaken in a cohort of young individuals from
ALSPAC. Tissue-specific analyses helped infer whether
individual or multiple genes were potentially responsible
for observed signals at each locus. Furthermore, moloc
suggested that changes in gene expression and proximal
DNA methylation may influence disease susceptibility at
the FADS1 locus.
Fig. 4 Manhattan plots illustrating associations with body mass index (BMI) across three different tissue types from Mendelian
randomization analyses: adipose subcutaneous (a), adipose visceral omentum (b) and whole blood (c). Chromosomal position of
genetic variants used as instrumental variables is plotted on the x-axis against −log10 P values from the Wald ratio on the y-axis.
Associations that survived the multiple testing threshold (1.9 × 10−7—represented by the red horizontal line) are coloured according
to the tissue type used
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with BMI in young individuals in previous studies [48,
49]. Our MR analyses identified evidence that changes
in ADCY3 expression in adipose tissues may influence
BMI, whereas weaker evidence was observed based on
the expression of other proximal genes (such as
NCOA1). Specifically, we found that the magnitude of
the effect for ADCY3 expression was observed most
strongly in adipose tissue, aligning with other research
[50, 51]. Furthermore, recent work has uncovered
loss-of-function variants in ADCY3 associated with an
increase in obesity levels [52]. In contrast, moloc showed
a lack of evidence of colocalization for NCOA1 expres-
sion. Moreover, although the CENPO gene was evaluated
as part of our original association analysis, there were no
eQTLs for this gene for any of the tissues we analysed.
From this, we believe that ADCY3 is likely the functional
gene impacting BMI at this locus (Fig. 1a: scenario 3), al-
though only with in-depth follow-up analyses can this be
determined with confidence. Our additional analysis in-
dicated no tissue-specific effects using eQTL effect esti-
mates derived from brain tissue, which suggests that the
influence of ADCY3 expression on BMI levels may be
confined to adipose tissue. However, extended analyses
using molecular data derived from brain tissue are ne-
cessary to confirm this, particularly given that previouswork has linked gene expression in brain tissue with
obesity-related traits [50, 53].
We also identified evidence of colocalization for gene
expression, DNA methylation and complex trait variation
at the cholesterol-associated region on chromosome 11.
This was observed for TMEM258 expression in whole
blood, although FADS1 narrowly missed the 0.8 cut-off
(PPA = 0.77). This was based on DNA methylation levels
at a CpG site located in the promoter region of FADS1
(cg19610905). This effect was observed using data from
whole blood (which is the only tissue we had accessible
DNA methylation for in this study), which is potentially
acting as a proxy for the true causal/relevant tissue type
for this effect [18]. However, there was no indication that
methylation played a role in the expression of FADS2.
TMEM258 has been proposed as a regulatory site for
cholesterol in ‘abdominal fat’ previously [54]. There is also
previously evidence of association between FADS1 and
cholesterol levels in young individuals [55]. Additionally,
genetic variation at this region is associated with DNA
methylation levels at cg19610905 based on cord blood in
ARIES, which suggests that these methylation changes
may influence the expression of FADS1/TMEM258 from
a very early age. Overall at this region, our results suggest
that scenario 2 (Fig. 1a) is a likely explanation for the asso-
ciation signal, where it is biologically plausible that
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Specifically, our analyses suggest that TMEM258 and
FADS1 are potential causal genes; however, further work
is needed to elucidate whether FADS2 is directly influen-
cing cardiovascular traits or is simply co-regulated with
nearby functional loci.
The LPL locus was not co-regulated with other genes
in our study and is therefore likely attributed to scenario
1 (Fig. 1a). LPL has been previously reported to influ-
ence lipid and triglyceride levels [56–58] which is sup-
ported by evidence from gene knockout experiments
[59]. The tissue specificity of LPL has also previously
been explored, although not by recent studies [60].
Two-sample MR analyses provided robust evidence that
this gene is strongly expressed in adipose tissue which
corroborates previous research [60, 61].
At other associated loci, the SORT1 locus has been
previously studied in detail with regard to its effect on
cholesterol levels [46, 62]. Our MR analyses provided
additional evidence of an effect using expression derived
from liver tissue for SORT1, CELSR2 and PSRC1, as well
as in pancreatic tissue for SORT1 and CELSR2 only. Our
subsequent moloc analysis identified evidence of coloca-
lization for SORT1 and CELSR2 expression with choles-
terol only in liver tissue, suggesting that PSRC1 could be
less tissue-specific than the other two genes in this re-
gion. Previous research supports these observations with
regard to the effects of SORT1 and CELSR2 in the liver
[11, 63], as well as the lack of tissue specificity for the
PSRC1 locus [64]. There was limited evidence that vari-
ation in this region colocalized with DNA methylation,
although future work with methylation data derived
from liver tissue is warranted.
Extending our analysis pipeline to leverage
summary-level data from large-scale consortia identified a
total of 233 association signals (220 excluding previous
findings in this study). Additionally, there was evidence
that genetic variants at these loci may also influence nearby
DNA methylation levels for 156 of these effects. As our
methylation data was derived from whole blood, these
findings support recent reports that whole blood may act
as a reliable proxy for other tissue types [21]. These results
can be harnessed to prioritize candidate genes which may
be responsible for the associations detected by GWAS.
Amongst findings, we identified evidence of association at
known loci which influence cardiovascular and anthropo-
metric traits, such as SLC5A11, SERPINC1 and INO80E
[65]. There was also evidence supporting potentially novel
loci, where findings from GWAS alone would not survive
multiple testing corrections. An example of this is CILP2, a
carbohydrate binding gene, which was associated with BMI
in our analysis.
There are also examples indicating that the integration
of tissue-specific gene expression can help developunderstanding into the biological mechanisms by which
these genes influence cardiovascular traits. For instance,
we identified evidence supporting POMC as responsible
for the association with BMI at its locus which was only
detected using pancreatic tissue data (PPA = 0.92).
Therefore, the most parsimonious explanation for this
finding may be that variation at this locus influences in-
sulin regulation via melanocortin peptides which are de-
rived from pro-opiomelanocortins (the product of
POMC) [66]. This finding also supports the evidence
that melanocortins play a role in insulin regulation
within the pancreas previously demonstrated in animal
models [67]. Furthermore, our colocalization results in-
dicate that the most likely scenario at this locus suggests
that DNA methylation may play a role in this effect
(PPA = 0.79), supporting previous findings that hyperme-
thylation of POMC influences obesity risk [68].
This study has demonstrated the value of our analysis
pipeline in terms of distinguishing between scenarios 1, 2,
3 and 4 (Fig. 1a). However, an important limiting factor, as
with any study applying single-instrument MR, is the in-
ability to separate mediation from horizontal pleiotropy
(i.e. scenario 5). Given that trans-eQTLs likely regulate
genes through a non-allele-specific mechanism [69], we
selected only eQTLs that were influencing proximal genes.
This is also a limitation of alternative approaches which
are comparable to ours, such as the SMR and eCAVIAR
methods [70, 71]. These methods have advantages over
our approach, for example, eCAVIAR allows multiple
causal variants to be identified in a region of interest,
whereas SMR routinely implements its colocalization ap-
proach (known as HEIDI) to help identify regions with
shared causal variants between traits. However, our ap-
proach also has advantages, such as investigating shared
causal variants for more than two traits (e.g. cardiovascu-
lar traits, gene expression and DNA methylation in this
study), whereas these alternatives are currently confined
to looking at a maximum of two traits. As more eQTLs
are uncovered across the genome by future studies, across
a wide range of tissue and cell types, our analysis pipeline
and other similar approaches should become increasingly
powerful to evaluate all five outlined scenarios.
In terms of limitations in this study, we recognize that
the varying sample sizes between tissues in GTEx will
determine the relative power to detect eQTL (Add-
itional file 1: Fig. S3). Increased sample sizes in GTEx
[72] and similar endeavours will help address this limita-
tion. Furthermore, the DNA methylation data we incor-
porated within our pipeline from the accessible resource
for ARIES [45] project was only obtained in whole blood.
This is a limitation as it relies on the assumption that
whole blood is acting as a proxy for another more relevant
tissue type to the disease of interest [73]. Although our
genome-wide results support recent findings indicating
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many loci where this is not the case. As such, future work
will need to incorporate DNA methylation data from vari-
ous tissues as and when these data become available to
help better understand the role of this epigenetic process
on transcriptional activity. This is a particularly important
question given recent evidence suggesting that promoter
DNA methylation may not be sufficient on its own to in-
fluence transcriptional changes [74]. Therefore, a resource
concerning tissue-specific DNA methylation would be ex-
tremely valuable.
Another constraint of relatively modest sample sizes in
GTEx is that we did not detect evidence of colocalization
at some loci despite investigating the functionally relevant
gene. For example, we can be reasonably certain that cir-
culating ApoA1 levels are influenced by the expression of
APOA1. The complexity of gene regulation is often under-
estimated due to factors such as feedback loops, hidden
confounders in expression data and regulatory activity not
always being detected in relevant tissues [75]. However,
we are beginning to better understand the regulation
across tissues [64], which should provide us with further
opportunities to detect cross-tissue regulatory activity and
develop our biological understanding of a disease. We also
note that fine-mapping and colocalization approaches
may be limited in their inference when applied to the re-
gions of the genome with extensive linkage disequilibrium,
such as the HLA region of the human genome. As such,
findings at these loci should be interpreted with caution,
particularly when evaluating association signals that exist
between multiple correlated traits such as the effect of
SORT1 in Additional file 2: Table S5 of our study.
Conclusions
We have identified a number of tissue-specific effects at
several regions throughout the genome. Our results sug-
gest that DNA methylation may also influence complex
traits through gene expression pathways. In-depth evalua-
tions of the loci identified in our study should help to fully
understand the causal pathway to disease for these effects.
Furthermore, as these genetic loci may influence cardio-
vascular traits early in the life course, these endeavours
should allow a long window of intervention for disease
susceptibility. Finally, the analysis pipeline outlined in this
study should prove particularly valuable for future studies
as increasingly large datasets concerning tissue-specific
gene expression become available.
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